Vanda Seeks FDA Commissioner Review of Outgoing CDER Director's Decision To Uphold Approval Of Two Generic Versions Of Hetlioz
RefinitivMenos de 1 minuto de leitura
Vanda Pharmaceuticals Inc VNDA:
VANDA SEEKS FDA COMMISSIONER REVIEW OF OUTGOING CDER DIRECTOR'S DECISION TO UPHOLD APPROVAL OF TWO GENERIC VERSIONS OF HETLIOZ®
Entrar ou criar uma conta gratuita para ler essa notícia